# A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

> **NCT06540833** · PHASE2 · RECRUITING · sponsor: **Intra-Cellular Therapies, Inc.** · enrollment: 370 (estimated)

## Conditions studied

- Psychosis Associated With Alzheimer's Disease

## Interventions

- **DRUG:** ITI-1284
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06540833
- **Lead sponsor:** Intra-Cellular Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2027-09
- **Final completion:** 2027-10
- **Target enrollment:** 370 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06540833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06540833, "A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06540833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*